Fig. 4. The promotion of chondrogenic differentiation by wedelolactone is weakened by FOXO1 inhibition. (A) Alcian blue and toluidine blue staining images of the chondrogenic differentiation of human iPSC-derived MSCs after different interventions. Quantification of the mean intensity of alcian blue and toluidine blue staining. (B) Gene expression analysis of the chondrogenic differentiation markers (COL2A1, SOX9, and ACAN) after wedelolactone and FOXO1 inhibitor (GSK126) intervention. Data are expressed as the mean±SD (n=3). Statistical differences were analyzed by one-way ANOVA followed by Dunnett’s test: *p<0.05, **p<0.01, ***p<0.001.

International Journal of Stem Cells 2023;16:326-41 https://doi.org/10.15283/ijsc22046

© 2023 International Journal of Stem Cells